Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Management of Hyperkalaemia in Patients with Cardiorenal Disease
Author(s): Antonio Méndez-Durán , Juan B Ivey-Miranda , Genaro H Mendoza-Zavala , et al Added: 1 month ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Hyperkalaemia in the Cardiorenal Patient - Navigating Guidelines & Real-World Data
Author(s): Clara Bonanad Lozano , Anjay Rastogi Added: 2 years ago
Dr Anjay Rastogi (David Geffen School of Medicine UCLA, US) and Dr Clara Bonanad (University Clinical Hospital of Valencia, ES) discuss the evolving management strategies of hyperkalaemia in heart failure and chronic kidney disease, in this short video series. In this three part discussion they cover the most recent guidelines from ACC, ESC and KDIGO, real-world evidence from the recent ZORA… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
The Aldosterone Story: New Chapters
Author(s): Vijay Chopra Added: 11 months ago

Heart Failure
TR in HFpEF: Prognosis Varies by Mechanism
Added: 6 months ago Source:  Radcliffe Cardiology
A new study published in JACC has evaluated the prevalence and prognostic significance of secondary tricuspid regurgitation (STR) across the spectrum of heart failure with preserved ejection fraction (HFpEF), finding that its presence is strongly associated with pulmonary vascular disease (PVD) and that different mechanisms of STR carry distinct prognoses.¹˒²This observational study analysed data… View more

Heart Failure
Iron Deficiency in LVAD Patients
Author(s): William Herrik Nielsen , Finn Gustafsson Added: 1 year ago

Heart Failure
Optimising RAASi Management in Cardiorenal Patients: An Expert Roundtable
Author(s): Andrew Frankel , Shelley Zieroth , Aaron Wong , et al Added: 2 years ago
In this on-demand version of the live roundtable, cardiologists Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA) and Dr Aaron Wong (Princess of Wales Hospital, Wales, UK) join nephrologists Dr Andrew Frankel (Imperial College Healthcare NHS Trust, London, UK), and Dr Manish Sood (University of Ottawa, CA) to discuss the nuanced landscape of RAASi management in cardiorenal patients.In… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Author(s): Ambarish Pandey Added: 1 year ago
ACC 2025 - In this highlights video, Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:STRIDESOULFRESH-UPFAIR-HF 2Recorded on-site at ACC in Chicago, 2025.Support: This is an independent interview produced by Radcliffe… View more

Prevention & Chronic Conditions

Heart Failure
THT 2025 Conference Announces its Late-Breaking Scientific Sessions
Added: 1 year ago Source:  THT
THT conference has released its four late-breaking trial sessions for 2025.The fourth annual Technology and Heart Failure Therapeutics conference is set to take place from the 11th to 13th February at Omni Boston Hotel at the Seaport in Boston. Access the full programme here.Late Breaking Clinical Science Session ITuesday 11th February, 09:30 – 10:45am ESTRobotic Surgical Technique for Performing… View more

Heart Failure
Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows
Added: 11 months ago Source:  Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and… View more

Cardiovascular Kidney Metabolic

Heart Failure